Research Group on Quality, Safety and Bioactivity of Plant Foods, CEBAS-CSIC, Murcia, Spain.
Ann N Y Acad Sci. 2013 Jul;1290:37-51. doi: 10.1111/nyas.12150.
Primary prevention of cardiovascular disease (CVD) aims to avoid a first event in subjects that are at risk but have not yet been diagnosed with heart disease. Secondary prevention of CVD aims to avoid new events in patients with established heart disease. Both approaches involve clinical intervention and implementation of healthy lifestyles. The grape and wine polyphenol resveratrol (3,5,4'-trihydroxy-trans-stilbene) has shown cardioprotective benefits in humans. Most of these approaches deal with rather high doses and short follow-ups, and do not address the issue of long-term resveratrol consumption safety, especially in medicated individuals. Here, we review the trials conducted with resveratrol in patients at risk for or with established CVD, focusing on the two longest human clinical trials reported so far (1-year follow-up). We also discuss the expectations for resveratrol from a dietary and clinical perspective in relation to CVD. However, statistically significant changes in CVD-risk markers do not necessarily equal clinical significance in the daily care of patients.
心血管疾病（CVD）的一级预防旨在预防尚未被诊断出患有心脏病的高危人群中的首次发病。CVD 的二级预防旨在预防已确诊心脏病患者的新发病例。这两种方法都涉及临床干预和健康生活方式的实施。葡萄和葡萄酒多酚白藜芦醇（3,5,4'-三羟基反式-二苯乙烯）已在人类中显示出心脏保护作用。这些方法大多数涉及较高剂量和较短的随访期，并未解决长期白藜芦醇消费安全性的问题，尤其是在用药个体中。在这里，我们综述了在有 CVD 风险或已确诊 CVD 的患者中进行的白藜芦醇试验，重点关注迄今为止报告的两项最长的人体临床试验（1 年随访）。我们还从饮食和临床角度讨论了白藜芦醇与 CVD 的关系。然而，CVD 风险标志物的统计学显著变化在患者的日常护理中不一定等同于临床意义。
